KOREA ALPHA

Technology

PIE battery vision inspection system illustrating a KRW 9.56 billion contract to expand AI inspection technology into ESS manufacturing.

PIE AI vision inspection technology connecting EV battery manufacturing with ESS production through automated defect detection and analysis.

PIE H1 2026 financial charts showing revenue growth of 60.9% year over year and an operating loss of KRW 6.08 billion.

PIE investment outlook diagram showing the progression from battery inspection orders to operating margins and sustainable cash generation.

Technology

Can PIE's New ESS Inspection Order Restore Profitability?

October 13, 2026 · 8 min

Intekplus semiconductor substrate inspection equipment examining a high-density chip substrate, highlighting its KRW 30.9 billion supply contract.

Advanced semiconductor packages, precision optical inspection equipment and defect detection images illustrating the importance of semiconductor manufacturing yield.

Intekplus financial infographic comparing KRW 126.2 billion in June 2026 order backlog with a KRW 7.0 billion operating loss in the first half of 2026.

Intekplus investment infographic showing the progression from semiconductor equipment order backlog to deliveries and operating margin improvement.

Technology

Intekplus Wins KRW 30.9B Order. Can Backlog Deliver Earnings?

October 12, 2026 · 7 min

Celltrion Q3 2026 earnings infographic showing KRW 510 billion operating profit and a 34.0% operating margin alongside biopharmaceutical manufacturing equipment.

Celltrion biosimilar profitability infographic illustrating newer biosimilars, an improving product mix and lower manufacturing costs.

Celltrion Q3 2026 year-on-year growth chart comparing revenue growth of 45.8% with operating profit growth of 69.2%.

Celltrion profitability outlook infographic highlighting product mix, pricing discipline and cash flow as key indicators of sustainable operating margins.

Technology

Celltrion's Record Q3 Earnings: Can 34% Margins Last?

October 12, 2026 · 9 min read

Samsung Electronics Q3 2026 record operating profit of KRW 107.4 trillion, illustrated with semiconductor wafer manufacturing equipment.

AI data center infrastructure and HBM memory chips illustrating rising demand for Samsung Electronics' high-performance DRAM.

Samsung Electronics Q3 2026 implied operating margin of 55.1%, with a chart comparing margins of 14.1%, 52.2% and 55.1%.

Samsung Electronics investment outlook showing memory pricing, operating margins and cash flow as three tests of earnings sustainability.

Technology

Samsung Electronics’ Record Q3 Profit: Why the Memory Boom Faces a Higher Bar

October 12, 2026 · 10 min read Copy

LG Energy Solution Q3 2026 earnings infographic showing KRW 756 billion in operating profit, up 25.7% year over year, over a battery production line.

LG Energy Solution ESS revenue growth infographic showing a 4.6-fold year-over-year increase in the first half of 2026, with grid-scale battery storage systems.

LG Energy Solution Q3 2026 profit comparison showing KRW 756 billion reported operating profit versus KRW 339.1 billion excluding US manufacturing tax credits.

LG Energy Solution ESS profitability roadmap illustrating production scale, operating margins and cash flow as key measures of sustainable earnings.

Technology

LG Energy Solution Q3 2026 Earnings: Can ESS Sustain the Rebound?

October 8, 2026 · 9 min

Hanmi Pharmaceutical GLP-1 obesity drug approval graphic featuring an injectable medicine vial and laboratory manufacturing equipment.

Eppe Phase 3 clinical trial infographic comparing 9.02% mean weight reduction with 0.89% for placebo after 40 weeks.

Hanmi Pharmaceutical infographic showing the path from Eppe prescriptions to repeat patient demand and recurring earnings.

Hanmi Eppe commercialization roadmap highlighting drug launch, patient adoption and sustainable profit margins as key milestones.

Technology

Can Hanmi Turn Korea's First Homegrown GLP-1 Approval Into Recurring Earnings?

October 8, 2026 · 10 min

EcoPro BM and Samsung SDI solid-state battery materials MOU illustrated with battery cells and electrolyte powders.

Exploded solid-state battery diagram highlighting sulfide solid electrolytes and advanced cathode materials developed by EcoPro BM.

EcoPro BM infographic comparing 40 tons of annual solid electrolyte pilot capacity with unproven commercial revenue.

EcoPro BM solid-state battery commercialization roadmap showing customer qualification, supply orders and profit milestones.

Technology

Can EcoPro BM Turn Samsung SDI's Solid-State Battery Partnership Into Earnings?

October 8, 2026 · 11 min

Taesung wins KRW 6.89 billion FC-BGA process equipment order worth 18.2% of 2025 revenue

AI and HPC demand drives advanced FC-BGA substrates and Taesung process equipment for etching, cleaning, plating and automation

Taesung expands production capacity six to seven times as 2026 cumulative orders surpass KRW 220 billion

Taesung investment outlook tracks FC-BGA orders through production, factory utilization and margins with glass substrates as upside

Technology

Can FC-BGA Orders Turn Taesung’s New Capacity Into Durable Earnings?

October 7, 2026 · 10 min

Alteogen expands beyond ALT-B4 with KRW 200 billion in new capital, biologics merger and manufacturing investment

Alteogen ALT-B4 biotech platform expands into drug development, manufacturing and commercialization

Alteogen 2026 estimated operating margin of 63.5 percent with KRW 492.4 billion revenue and KRW 312.7 billion operating profit

Alteogen capital allocation from ALT-B4 cash flows into new pipelines, manufacturing and profitable growth

Technology

Can Alteogen Expand Beyond ALT-B4 Without Diluting Its Platform Economics?

October 7, 2026 · 11 min

Samsung Biologics KRW 93.5 billion European pharmaceutical CDMO contract through 2031

Samsung Biologics CDMO expansion across Plant 5, U.S. manufacturing and peptide production

Samsung Biologics H1 2026 revenue KRW 2.58 trillion, operating profit KRW 1.17 trillion and 45.3% operating margin

Samsung Biologics investment path from Plant 5 and M&A to utilization and capital returns

Technology

Can Samsung Biologics Broaden Its CDMO Platform Without Diluting Returns?

October 6, 2026 · 11 min